NCT06915922 · VMR Consulting, Inc.
YAG Laser Vitreolysis for Vitreous Floaters
(YLV Protocol)
What this study is about
The purpose of this study is to measure how the quality of life, the structure of eye, and vision change after treatment for the opacities in the gel (vitreous) that fills the center of eye which cause vision disturbances commonly called "floaters". In this study the vitreous floaters are treated using a Neodymium-doped yttrium-aluminum-garnet (Nd:YAG) laser.
View original scientific description
The purpose of this study is to measure how the quality of life, the structure of eye, and vision change after treatment for the opacities in the gel (vitreous) that fills the center of eye which cause vision disturbances commonly called "floaters". In this study the vitreous floaters are treated using a Neodymium-doped yttrium-aluminum-garnet (Nd:YAG) laser. The FDA has approved the use of this laser to treat membranes in the eye.
Interventions
DEVICE
Neodymium-doped yttrium-aluminum-garnet (Nd:YAG) laser therapy
Nd:YAG laser treatment(s) for Vision Degrading Myodesopsia (clinically significant vitreous floaters) in eyes with vitreous opacities due to myopic vitreopathy and posterior vitreous detachment (PVD).
Primary outcome measures
Measures of vitreous structure by quantitative ultrasonography
Time frame: baseline, 3 months, 6 months, 12 months
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Only one eye per patient will be included in this study
- Able and willing to give informed consent
- Age ≥18 years
- Suffering from symptomatic vitreous floaters
- Floaters arising from either/both:
- myopic vitreopathy
- posterior vitreous detachment
- Floaters meeting the following characteristics:
- Present for ≥3 months
- One single or more dense and well-defined vitreous opacities,
- A Weiss Ring or opacities which are within the safety area, at least 3mm away from the retina and 6mm away from the lens
- Visible on contact lens biomicroscopy
Exclusion criteria
- Patient presenting with vitreous opacities outside of the described safety area (within 3mm of the retina or 6mm from the lens)
- Have clinically significant cataract (lens opacification) in one or both eyes which are in the opinion of the examining doctor more significant in impacting vision as compared to that caused by vitreous opacities; or cataract expected to need cataract surgery during the duration of the study
- Present with untreated retinal tears or retinal holes requiring treatment at the discretion of the study investigator
- Have high risk of peripheral lesions requiring treatment at the discretion of the study investigator
- Have synchysis scintillans (unusual vitreous opacities from old blood)
- Have asteroid hyalosis (unusual vitreous opacities from cholesterol)
- Have vitreous hemorrhage (fresh blood in the center of the eye)
- Have active photopsia (flashing lights)
- History of previous YAG laser vitreolysis treatments, or vitrectomy for any condition (retinal detachment, proliferative diabetic retinopathy, etc.)
- Have Posterior Vitreous Detachment (separation of vitreous away from the retina lining the inside of the back of the eye) within the past 3 months
- Are unable to attend study appointments
- Have any other significant ocular or non-ocular condition that, at the discretion of the study investigator, puts the subject at risk or influences the results of the study
- History of intraocular surgery within 6 months from study entry
- History of retinal laser within 2 months from study entry
Where
- Huntington Beach, California
Collaborators
The Retina Clinic - London Ophthalmic Institute
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Feb 27, 2026 · Source of record for eligibility and locations